Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo targets Post-Transplant cancer in early trial

NCT ID NCT07573436

Not yet recruiting Disease control Sponsor: University of Utah Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This early-phase trial is testing a combination of two drugs, loncastuximab tesirine and rituximab, as a first treatment for a rare blood cancer called post-transplant lymphoproliferative disorder (PTLD) that can occur after an organ transplant. The study will first find the safest dose (phase 1) and then check how well the drugs work (phase 2) in 23 adults. The goal is to see if this combination can shrink or eliminate the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
loncastuximab tesirine and rituximab
What this could lead to
If this works, it could offer a new first-line treatment option for post-transplant lymphoproliferative disorder, potentially improving response rates and reducing the need for more toxic therapies.
What could go wrong
This is an early phase 1/2 trial with only 23 participants, so results are preliminary. The combination may cause significant side effects, and it's not yet known if it will be more effective than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

post-transplant lymphoproliferative disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER

Contacts and locations

Locations

  • Huntsman Cancer Institute at University of Utah

    Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.